Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs. 28.3) and the median overall survival was longer (14.7 vs. 9.6 months) among patients who received azacitidine plus venetoclax (a B-cell lymphoma...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-08, Vol.383 (7), p.617-629
Hauptverfasser:	DiNardo, Courtney D, Jonas, Brian A, Pullarkat, Vinod, Thirman, Michael J, Garcia, Jacqueline S, Wei, Andrew H, Konopleva, Marina, Döhner, Hartmut, Letai, Anthony, Fenaux, Pierre, Koller, Elizabeth, Havelange, Violaine, Leber, Brian, Esteve, Jordi, Wang, Jianxiang, Pejsa, Vlatko, Hájek, Roman, Porkka, Kimmo, Illés, Árpád, Lavie, David, Lemoli, Roberto M, Yamamoto, Kazuhito, Yoon, Sung-Soo, Jang, Jun-Ho, Yeh, Su-Peng, Turgut, Mehmet, Hong, Wan-Jen, Zhou, Ying, Potluri, Jalaja, Pratz, Keith W
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Age Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Azacitidine - administration & dosage Azacitidine - adverse effects Blood platelets Bone marrow Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Bridged Bicyclo Compounds, Heterocyclic - adverse effects Cancer therapies Chemotherapy Double-Blind Method Female Flow cytometry Follow-Up Studies Humans Hydration Induction therapy Intention to Treat Analysis Kaplan-Meier Estimate Laboratories Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Leukopenia - chemically induced Male Medical prognosis Middle Aged Myeloid leukemia Nausea Neutropenia Neutrophils Oral administration Pneumonia - etiology Proteins Quality of life Questionnaires Recurrence Remission Remission Induction Sulfonamides - administration & dosage Sulfonamides - adverse effects Survival Thrombocytopenia Thrombocytopenia - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs. 28.3) and the median overall survival was longer (14.7 vs. 9.6 months) among patients who received azacitidine plus venetoclax (a B-cell lymphoma 2 antagonist) than among those who received azacitidine alone.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2012971